Request Demo

Last update 14 Apr 2025

Tamsulosin Hydrochloride

Last update 14 Apr 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryTamsulosin was approved for medical use in the United States in 1997. Specifically it is an α1 adrenergic receptor blocker. Tamsulosin, sold under the brand name Flomax among others, is a medication used to treat symptomatic benign prostatic hyperplasia (BPH) and chronic prostatitis and to help with the passage of kidney stones. The evidence for benefit with a kidney stone is better when the stone is larger. It is taken by mouth. Common side effects include dizziness, headache, sleeplessness, nausea, blurry vision, and sexual problems. Other side effects may include feeling lightheaded with standing and angioedema. Tamsulosin is an alpha blocker and works by relaxing muscles in the prostate.

Drug Type

Small molecule drug

Synonyms

(-)-tamsulosin, (R)-(-)-tamsulosin, (R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide

+ [36]

Target

α1A-AR

Action

antagonists

Mechanism

α1A-AR antagonists(Alpha-1a adrenergic receptor antagonists)

Therapeutic Areas

Urogenital DiseasesOther Diseases

Active Indication

Lower Urinary Tract SymptomsProstatic Hyperplasia

Inactive Indication

Acute retention of urineDysuriaErectile Dysfunction+ [5]

Originator Organization

Astellas Pharma, Inc.

Active Organization

Astellas Pharma Europe BV

Astellas Pharma, Inc.Astellas Pharma Australia Pty Ltd.

+ [2]

Inactive Organization

Boehringer Ingelheim GmbH

Astellas Pharma China, Inc.Astellas Pharma Europe Ltd.

+ [1]

Drug Highest PhaseApproved

First Approval Date

Japan (02 Jul 1993),

Prostatic Hyperplasia

RegulationPriority Review (China)

Structure/Sequence

Molecular FormulaC20H29ClN2O5S

InChIKeyZZIZZTHXZRDOFM-XFULWGLBSA-N

CAS Registry106463-17-6

316

Clinical Trials associated with Tamsulosin Hydrochloride

NCT06803030

/ Not yet recruitingPhase 3IIT

A Comparative Study on the Efficacy of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms: a Randomized Controlled Trial

A comparative study on the efficacy of Tamsulosin, Solifenacin and Mirabegron in alleviating ureteral stent-related symptoms: a randomized controlled trial.

Start Date01 Apr 2025

Sponsor / Collaborator

Bir Hospital

NCT06865430

/ RecruitingNot ApplicableIIT

Management of Dysuria and Irritative Symptoms After HoLEP: a Prospective Study Evaluating the Efficacy of Alpha-Blocker Therapy

Holmium Laser Enucleation of the Prostate (HoLEP) is an increasingly popular endoscopic minimally invasive surgical technique for the treatment of benign prostatic hyperplasia (BPH). In the literature, the long-term efficacy and low complication rates of HoLEP have been highlighted in many studies. However, in the early postoperative period, particularly within the first three months, irritative symptoms are reported in 17-35% of cases (1-2).
The pathophysiology of postoperative irritative symptoms is not yet fully understood, but it has been suggested that these symptoms may be associated with urethral trauma, the mucosal healing process, and detrusor overactivity. These symptoms can significantly impact quality of life, reducing patient satisfaction. In particular, dysuria is a frequently encountered symptom after HoLEP, with considerable individual variability in its severity and duration.
The effectiveness of alpha-blockers in alleviating postoperative dysuria and irritative symptoms remains a topic of debate in the literature. Although prostate tissue is surgically removed, alpha-blockers may improve urinary flow and relieve symptoms associated with bladder outlet obstruction by reducing urethral smooth muscle tone (3). Studies on the use of alpha-blockers following transurethral resection of the prostate (TURP) have shown limited postoperative benefits (4). However, to the best of our knowledge, no study has specifically evaluated their use following HoLEP, an enucleation-based technique. Therefore, further studies are needed to assess the role of alpha-blockers in managing dysuria after HoLEP.
The aim of this study is to evaluate the effectiveness of alpha-blocker therapy in managing dysuria and other irritative symptoms following HoLEP. Additionally, the study seeks to determine the impact of this treatment on quality of life and patient satisfaction.

Start Date04 Mar 2025

Sponsor / Collaborator-

NCT06843538

/ RecruitingPhase 3

Peri-operative Tamsulosin and Impact on Voiding Trial Following Outpatient Urogynecology Surgery: a Randomized Controlled Trial

The purpose of this research study is to determine if taking tamsulosin preoperatively decreases your chances of being discharged after surgery with a Foley catheter (flexible tube that drains urine from the bladder into a collection bag).

Start Date03 Feb 2025

Sponsor / Collaborator

TriHealth, Inc.

100 Clinical Results associated with Tamsulosin Hydrochloride

100 Translational Medicine associated with Tamsulosin Hydrochloride

100 Patents (Medical) associated with Tamsulosin Hydrochloride

3,179

Literatures (Medical) associated with Tamsulosin Hydrochloride

01 Jun 2025·AMERICAN JOURNAL OF OPHTHALMOLOGY

Unplanned Return to the Operating Room After Cataract Surgery

Article

Author: Suazo, Mallory K ; Akhlaq, Anam ; Khan, Malik Muhammad Hamza ; Schein, Oliver D ; Ali, Muhammad ; Woreta, Fasika A

PURPOSE:

To determine the rate of unplanned return to the operating room (OR) within 90 days of cataract surgery and to identify the most common preoperative and intraoperative risk factors.

DESIGN:

Retrospective case-control study.

SUBJECTS AND CONTROLS:

Patients aged ≥40 years undergoing cataract surgery at the Wilmer Eye Institute between 2019 and 2022 with at least 90 days of postoperative follow-up were included. Patients with return to the OR for a reason other than a postoperative complication of cataract surgery in the same eye were excluded. For each case, a time-matched control (cataract surgery within 1 month of the case's surgery) was selected using a random number generator.

METHODS:

The chi-squared test was used for categorical variables, the student's t-test for continuous variables, and the multivariable logistic regression analysis to assess for associated preoperative and intraoperative factors.

MAIN OUTCOME MEASURES:

The main outcomes included the rate and the most common reasons for unplanned return to the OR as well as the odds ratios of associated preoperative and intraoperative variables.

RESULTS:

Among 32,480 eyes, 175 eyes (0.54%) had an unplanned return to the OR within 21 ± 21 days of cataract surgery. The most common reason was retained lens fragments in 88 eyes (50%). Patients with an unplanned return to the OR had a worse mean best-corrected visual acuity preoperatively (Snellen equivalent of ∼20/100 for cases vs 20/50 for controls, p-value < .001) and at last follow-up (cases 20/50, controls 20/30, p-value < .001). There were significantly higher odds of an unplanned return to the OR for patients undergoing complex cataract surgery (odds ratio, 1.80; 95% CI, 1.06-3.05) and for patients with prior tamsulosin use (odds ratio, 2.00; 95% CI, 1.09-3.69).

CONCLUSIONS:

Patients undergoing complex cataract surgery and those with prior tamsulosin use had significantly higher odds of unplanned return to the OR. Monitoring rates of unplanned return to the OR at the institutional and national levels by using national clinical registries or a multicenter study is needed to assist in quality monitoring and to improve patient surgical outcomes.

01 May 2025·DRUG SAFETY

Network Analysis and Machine Learning for Signal Detection and Prioritization Using Electronic Healthcare Records and Administrative Databases: A Proof of Concept in Drug-Induced Acute Myocardial Infarction

Article

Author: Ágg, Bence ; Ferdinandy, Péter ; Balogh, Olivér M ; Spina, Edoardo ; Sessa, Maurizio ; Casula, Manuela ; Battini, Vera ; Rossi, Andrea ; Barbieri, Maria Antonietta ; Abate, Andrea ; Pétervári, Mátyás ; Carnovale, Carla ; Cocco, Marianna

BACKGROUND:

Safety signals for potential drug-induced adverse events (AEs) typically emerge from multiple data sources, primarily spontaneous reporting systems, despite known limitations. Increasingly, real-world data from sources such as electronic health records (EHRs) and administrative databases are leveraged for signal detection. Although network analysis has shown promise in mapping relationships between clinical attributes for signal detection in spontaneous reporting system databases, its application in real-world data from EHRs and administrative databases remains limited.

OBJECTIVE:

This study aimed to evaluate the performance of network analysis in detecting safety signals within Italian administrative databases, using drug-induced acute myocardial infarction (AMI) as a proof of concept.

METHODS:

We employed a case-crossover design to explore the association between drug exposure and AMI using the Healthcare Administrative Database of Mantova, Italy, from 2014 to 2018. Patients with their first AMI hospitalization were identified after a 365-day washout period to exclude prior hospitalizations. We constructed a network to analyse the relationships between prescribed drugs and diagnoses, represented as nodes, with undirected edges illustrating their interactions. For each patient with AMI, we identified all diagnoses and drugs recorded or redeemed within 365 days of the first AMI episode and generated various drug-diagnosis, drug-drug, and diagnosis-diagnosis pairs. We calculated the frequency of these pairs, and three types of edge weights quantified the strength of connections. We identified outlier drug-AMI pairs using a predictive score (F) based on frequency (C) and full edge weights (W_F), with validation for known AMI associations. We prioritized signals using the F score, C of AMI, and W_F, analysed through k-means clustering to identify patterns in the data.

RESULTS:

From 2014 to 2018, a total of 3918 patients had an AMI, with 4686 AMI diagnoses. Of those, 2866 had prescriptions in the previous year, totalling 498,591 prescriptions. A network analysis identified 2968 unique nodes, revealing 529,935 diagnosis-diagnosis connections, 235,380 drug-diagnosis connections, and 102,831 drug-drug connections. The median number of connections (C) was 404 (Q1-Q3: 194-671) for drug nodes and 380 (Q1-Q3: 216-664) for diagnosis nodes. The median W_F was 11.8 (Q1-Q3: 9-14), and the median F score across pairs was 0.1 (Q1-Q3: 0.1-0.3). A total of 249 potential safety signals were detected, with 63.4% aligning with known AEs. Among the remaining signals, 80 were prioritized, and five emerged as the highest priority: terazosin, tamsulosin, allopurinol, esomeprazole, and omeprazole.

CONCLUSIONS:

Overall, our novel method demonstrates that network analysis is a valuable tool for signal detection and prioritization in drug-induced AEs based on EHRs and administrative databases.

03 Apr 2025·Drug metabolism and personalized therapy

CYP2D6 genetic polymorphisms impact on tamsulosin efficacy and safety in patients with benign prostatic hyperplasia

Article

Author: Abdullaev, Shokhrukh ; Sychev, Dmitry ; Teodorovich, Oleg ; Bochkov, Pavel ; Sychev, Ivan ; Shatokhin, Maksim ; Abdullaev, Sherzod ; Tuchkova, Svetlana ; Loran, Oleg ; Krasnov, Aleksandr

Abstract:

Objectives:

The clinical outcomes of tamsulosin therapy for LUTS/BPH patients vary, with up to one-third of patients reporting unsatisfactory results. Enhancing the effectiveness and safety of tamsulosin therapy for LUTS/BPH patients remains a significant challenge in current medical practice. Limited data exists regarding the impact of CYP2D6 genetic polymorphisms on the efficacy and safety of tamsulosin therapy. Given that tamsulosin is metabolized by CYP2D6, variations in this enzyme may influence the drug's pharmacodynamic response. The objective of this study was to evaluate the impact of CYP2D6 pharmacogenetic markers on tamsulosin efficacy and safety in patients with LUTS associated with BPH.

Methods:

The study included 142 male patients with LUTS and a confirmed diagnosis of BPH (N40 ICD-10). Patients were followed for a minimum of 8 weeks and underwent four examinations (at days 0, 14, 28, and 56). Treatment efficacy was assessed using the IPSS with quality of life assessment, transrectal ultrasound of the prostate with estimation of prostate volume and residual urine volume, and maximum urinary flow rate (Qmax). Allelic variants of CYP2D6 (*2, *3, *4, *6, *9, *10, and *41) were determined by polymerase chain reaction in all patients..

Results:

In the subgroup with moderate symptoms, individuals classified as poor and intermediate metabolizers exhibited significantly higher ΔQmax compared to normal metabolizers (4.25 [2.5; 6.1] vs. [0.6; 4.3], p=0.001826). Moreover, carriers of the CYP2D6*10 CT heterozygous genotype demonstrated lower IPSS scores at the last two visits compared to those with the CC genotype (visit 3: −7.45 ± 3.93 vs. −5.25 ± p=0.05; visit 4: −8.91 ± 3.88 vs. −6.31 ± 5.7), as well as reduced IPSS irritative symptoms at visit 2 (−3.87 ± 2.70 vs −2.47 ± 3.1, p=0.05), and a significant increase in ΔQmax ([2.5; 5.9] vs. [0.6; 4.7], p=0.01). In the subgroup with severe symptoms, individuals with CYP2D6*41 GA + AA genotypes exhibited less residual urine volume following therapy compared to those with the GG genotype ([15.0; 32.0] vs. [3.0; 19.0], p=0.007029). The CYP2D6 polymorphic variants did not impact the tamsulosin safety. The study did not reach the estimated power for CYP2D6*3, CYP2D6*6, and CYP2D6*9 polymorphisms due to their low frequency of occurrence in the study population. The multivariate logistic regression model indicated that potential predictors of tamsulosin therapy efficacy in LUTS/BPH patients may include BMI (p<0.001), prostate volume (p<0.002), as well as the carriage of CYP2D6*4 (p<0.001) and CYP2D6*10 (p=0.012) markers. The model explained 81.9 % of the variance in the predicted outcome and accurately forecasted tamsulosin therapy efficacy in BPH with a precision of 92.1 %.

Conclusions:

The present study identified potential markers that could serve as predictors of the effectiveness of tamsulosin. Specifically, genetic markers such as CYP2D6*4, CYP2D6*10, CYP2D6*41, and non-genetic factors like BMI and prostate volume were associated with the clinical efficacy of tamsulosin therapy in LUTS/BPH patients..

News (Medical) associated with Tamsulosin Hydrochloride

02 Apr 2025

·www.prnewswire.com

Hanmi Pharmaceutical's 'Gugutams' to be Launched in Mexico as 'Aditams', Marking the Start of Full-Scale Latin America Expansion

Hanmi Pharm Begins Local Sales of Urological Product 'Aditams' in Mexico with Partner 'Laboratorios Silanes' Launch completed in February, Hanmi Pharm's Third Product to Enter Latin America Aditams, The First Urological Combination Drug for OPG and ED Exported to Mexico SEOUL, South Korea, April 2, 2025 /PRNewswire/ -- Hanmi Pharmaceutical's combination therapy for Obstructive Prostatic Growth (OPG) caused by Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED), Gugutams, is entering the Mexican market under the local brand name "Aditams." Continue Reading Aditams Hanmi Pharmaceutical announced that it has completed the launch of Aditams in Mexico under the export agreement signed in October 2020 with the Mexican pharmaceutical company 'Laboratorios Silanes'. Under the agreement, Hanmi Pharmaceutical plans to export Gugutams to the Mexican market for a period of seven years, starting in February 2025. Gugutams, developed by Hanmi Pharmaceutical, is the world's first urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). It is also noteworthy as the first prescription drug in Korea to apply Poly-Cap technology, which integrates multiple active ingredients into a single capsule. Laboratorios Silanes, a leading pharmaceutical company in Mexico founded in 1943, is committed to providing innovative healthcare solutions and driving rapid growth in the industry. It has established itself as a key player in the Latin American pharmaceutical market through its robust distribution network and strategic collaborations with global partners. Silanes previously collaborated with Hanmi Pharmaceutical in 2023 to successfully introduce the hypertension and dyslipidemia combination treatment 'Amosartan Q', under the local brand 'Lodarta' and in 2024 to introduce the combination hypertension treatment 'Amosartan Plus' under the local brand 'Bicartial-CTD'. Following these products, Gugutams, under the local brand 'Aditams', becomes Hanmi Pharmaceutical's third product in the Latin American region. Aditams, as the first urological combination therapy to enter the Mexican market, is expected to offer a new treatment option for patients suffering from both Obstructive Prostatic Growth (OPG) and erectile dysfunction (ED). By managing both conditions with a single medication, it significantly enhances patient convenience and maximizes therapeutic efficacy. Hanmi continues to focus on expanding its partnerships in emerging markets such as the Middle East and Latin America, in addition to its established presence in developed markets like North America and Japan. The company aims to leverage strategic partners like Laboratorios Silanes as key footholds to broaden its product portfolio and regional reach. Park Jae-hyun, CEO of Hanmi Pharmaceutical, stated, "As the first urological combination therapy to enter the Mexican market, Gugutams is expected to present a new treatment paradigm for local patients." He added, "Through this collaboration with Laboratorios Silanes, we aim to solidify Hanmi Pharmaceutical's presence in the Latin American market and leverage this as a foundation to further strengthen our competitiveness in the global pharmaceutical industry." Official Websites: About Hanmi Pharmaceutical: Hanmi Pharmaceutical is an R&D-focused pharmaceutical company committed to developing globally innovative therapies in areas of high unmet medical needs such as obesity/metabolism, oncology, and rare diseases. Hanmi leverages proprietary platform technologies, including long-acting biologics and bispecific antibodies, to address unmet medical needs. The company emphasizes open innovation and has established numerous global partnerships to advance its research and development efforts. SOURCE Hanmi Pharmaceutical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalLicense out/inBiosimilar

21 Jun 2024

·pmlive.com

Study suggests enlarged prostate drugs could protect against dementia with Lewy bodies

Researchers from the University of Iowa (UI) Health Care have suggested that certain drugs used to treat enlarged prostates have the potential to decrease the risk of dementia with Lewy bodies (DLB). Published in Neurology , the study revealed that three enlarged prostate drugs were able to increase the energy production in brain cells. Affecting one in every 1,000 people per year, DLB is the second most common type of dementia, which occurs when protein deposits called Lewy bodies develop in nerve cells in the brain, affecting thinking, memory and movement. Researchers identified more than 643,000 men with no history of DLB who were newly starting one of six drugs used to treat benign prostatic hyperplasia and followed the participants for around three years from when they started taking the medication until they left the database or developed DLB. The observational study found that the already-approved Abbott’s Hytrin (terazosin), Pfizer’s Cardura (doxazosin) and Sanofi’s Uroxatral (alfuzosin) boosted the energy production in brain cells, which could help to slow or prevent neurodegenerative diseases including DLB and Parkinson’s disease (PD), while the three other drugs, tamsulosin and two 5-alpha-reductase inhibitors (5ARIs), finasteride and dutasteride, did not. Men who took terazosin had around a 40% lower risk of developing DLB versus men taking tamsulosin and about a 37% reduction in risk compared to men taking 5ARIs, with no statistically significant difference in risk between men taking tamsulosin and ARIs. “If terazosin and these similar medications can help slow this progression – if not outright preventing the disease – this would be important to preserving cognitive function and quality of life in people with DLB,” said lead study author, Jacob Simmering, UI assistant professor, internal medicine. Previous studies have already linked certain drugs and treatments to other neurodegenerative conditions. In February, researchers from University College London revealed that erectile dysfunction drugs could also be linked to a reduced risk of developing Alzheimer’s disease (AD), the most common form of dementia. Of nearly 270,000 men over the age of 40, those who were prescribed phosphodiesterase 5 inhibitors were 18% less likely to develop AD compared to those who were not.

Clinical ResultDrug Approval

20 Jun 2024

·www.biospace.com

Prostate Drugs May Find New Use in Reducing Risk of Dementia: Study

Pictured: Concept art showing an elderly woman overlaid with an illustration of a brain/iStock, boonstudio Drugs commonly used for the treatment of enlarged prostate may also help lower the risk of dementia with Lewy bodies, according to a new observational study from the University of Iowa Health Care. Drawing from Merative MarketScan, one of the largest proprietary U.S. healthcare claims databases, University of Iowa researchers identified more than 643,000 men who were starting treatment for benign prostatic hyperplasia with one of six common therapies. Three of these drugs fell under the class of α-1 adrenergic receptor antagonists, better known as α-blockers, which work by inhibiting the contraction of smooth muscles. The researchers focused on terazosin, which is sold by Abbott under the brand name Hytrin, doxazosin, which is marketed by Pfizer as Cardura, and alfuzosin, which is branded as Uroxatral by Sanofi. Alpha-blocker drugs are known to have a unique side effect: they activate a key enzyme involved in the production of ATP, which is the molecular form of cellular energy. In the brain, these drugs can help boost the production of energy and fight neurodegeneration, the University of Iowa scientists hypothesized. As active comparators, the researchers also followed men in Merative MarketScan who were being treated with tamsulosin or with the 5α-reductase inhibitors (5ARI) finasteride and dutasteride, all of which are not known to affect energy production in the brain. The men included in the study had no history of dementia with Lewy bodies (DLB). Participants were then followed until they exited the database or until they developed DLB. After an average follow-up of around three years, the study found that men who were initiated on the three alpha-blocker drugs were 40% less likely to develop DLB than comparators who were on tamsulosin. Compared with men whose enlarged prostates were being treated with 5ARI agents, the risk of DLBA was 27% lower in those taking alpha-blocker drugs. Both effects were statistically significant. By contrast, DLB had a statistically similar likelihood of developing in men being managed with tamsulosin and 5ARIs. These results were robust to several sensitivity analyses, according to researchers. The University of Iowa scientists published their findings Wednesday in Neurology, the medical journal of the American Academy of Neurology. “If terazosin and these similar medications can help slow this progression—if not outright preventing the disease—this would be important to preserving cognitive function and quality of life in people with DLB,” Jacob Simmering, assistant professor of internal medicine at the University of Iowa and lead study author, said in a statement. However, the researchers caution that the study is simply observational in design and only shows that there is a statistical correlation between the use of alpha-blocker drugs and the reduced risk of DLB. It does not establish causation nor does it show any directionality of association, they said. Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

Clinical Result

100 Deals associated with Tamsulosin Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01024	Tamsulosin Hydrochloride	G04CA02	DB00706

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Lower Urinary Tract Symptoms	Belgium	Astellas Pharma Europe BV	01 Mar 2005
Lower Urinary Tract Symptoms	Luxembourg	Astellas Pharma Europe BV	01 Mar 2005
Hypertension	United States	Sanofi-Aventis U.S. LLC	15 Apr 1997
Prostatic Hyperplasia	Japan	Astellas Pharma, Inc.	02 Jul 1993

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Urological Manifestations	Phase 3	United States	Boehringer Ingelheim GmbH	23 Sep 2015
Urinary Bladder, Neurogenic	Phase 3	United States	Boehringer Ingelheim GmbH	01 Jan 2008
Urinary Bladder, Neurogenic	Phase 3	Belgium	Boehringer Ingelheim GmbH	01 Jan 2008
Urinary Bladder, Neurogenic	Phase 3	Brazil	Boehringer Ingelheim GmbH	01 Jan 2008
Urinary Bladder, Neurogenic	Phase 3	Germany	Boehringer Ingelheim GmbH	01 Jan 2008
Urinary Bladder, Neurogenic	Phase 3	India	Boehringer Ingelheim GmbH	01 Jan 2008
Urinary Bladder, Neurogenic	Phase 3	Italy	Boehringer Ingelheim GmbH	01 Jan 2008
Urinary Bladder, Neurogenic	Phase 3	Mexico	Boehringer Ingelheim GmbH	01 Jan 2008
Urinary Bladder, Neurogenic	Phase 3	Philippines	Boehringer Ingelheim GmbH	01 Jan 2008
Urinary Bladder, Neurogenic	Phase 3	Russia	Boehringer Ingelheim GmbH	01 Jan 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03750656 (HyTa Stent, CTgov)	Phase 4	Lower Urinary Tract Symptoms	5	Hyoscyamine (Hyoscyamine)	neridfpjci(fsxfapkkmz) = ufsavklobp wzvylpzdiv (rolrejeivs, wgzjxgmfya - lqmwtpgiau) View more	-	03 Dec 2024
				Tamsulosin (Tamsulosin)	neridfpjci(fsxfapkkmz) = odtzujxvry wzvylpzdiv (rolrejeivs, erzenxjbaa - gnncfiymdy) View more
NCT01568918 (CTgov)	Phase 3	Urinary Retention	90	Tamsulosin hydrochloride (Tamsulosin)	pmrtsfimnn = ujendasowf zcirnsgfey (zyicvoxzfi, auyxiyisou - spjvkfoknl) View more	-	30 May 2024
				Placebo (Placebo)	pmrtsfimnn = mftsjmsgia zcirnsgfey (zyicvoxzfi, rbchkmjbfi - ctukznxxgb) View more
MP26-09 (AUA2024)	Not Applicable	-	200	Tamsulosin	grhbzpqlul(kbpwoeecuk) = pvevmemfpx iohvlwxwuz (tfcksydfdc )	Positive	01 May 2024
				Placebo	grhbzpqlul(kbpwoeecuk) = cwrplibhxc iohvlwxwuz (tfcksydfdc )
NCT04859660 (A Randomized Controlled Trial, CTgov)	Phase 2	Urinary Retention	161	Tamsulosin (Tamsulosin- Intervention Group)	fphrquqlmv(klbyhokqmk) = aegovocdqp rtdckkhgpi (reuisirdoc, dnohgqzzca - cwnamocmzy) View more	-	29 Feb 2024
				Placebo (Placebo Group)	fphrquqlmv(klbyhokqmk) = yqgfhyzdvl rtdckkhgpi (reuisirdoc, dmzqsnypsc - qukqatnfxt) View more
NCT04682366 (CTgov)	Phase 4	Urinary Retention	4	Tamsulosin (Tamsulosin)	xpvbmgzqlj = pyrqflcdad amcquircrd (cukzvxdfdp, zbeiyavbni - dgvpqdtgth) View more	-	31 Jan 2024
				Placebo (Placebo)	xpvbmgzqlj = tgfisgjdqs amcquircrd (cukzvxdfdp, awmevwekmu - qppngtfsgr) View more
MP24-17 (AUA2023)	Not Applicable	Prostatic Hyperplasia	160	Tamsulosin	epjlncibwd(jyqrwgthph) = xwvlfemsxz hyhfpssapi (ktyurpaiuu )	-	01 Apr 2023
				Tadalafil 5 mg	epjlncibwd(jyqrwgthph) = oqyvpvmzcw hyhfpssapi (ktyurpaiuu )
APAO2023	Not Applicable	Intraoperative floppy iris syndrome (IFIS) Tamsulosin	54	Tamsulosin	ymnqzsmgil(cwzjjvumxm) = umctruebjk qezfjecyhz (lbbhigjnuc )	Positive	23 Feb 2023
NCT04819828 (Pubmed \| Int J Clin Pract)	Phase 4	Kidney Calculi Adjuvant	60	Tamsulosin	yvhheonhjc(ahzxkyrond) = ngudifczkh mdcogtqfuw (oxyswyqyoi )	Negative	01 Jan 2022
				tamsulosin (Control)	yvhheonhjc(ahzxkyrond) = quicakkgyw mdcogtqfuw (oxyswyqyoi )
NCT03524339 (CTgov)	Phase 2/3	Pelvic Organ Prolapse \| Urinary Incontinence, Stress \| Urinary Retention ... View more	132	Placebo oral capsule (Placebo)	vnnkjdsvyc = heqbpkbkwg xjjnzzerse (nnyzjnojya, ucafgnirms - zpgnqqvzhe) View more	-	08 Nov 2021
				Tamsulosin (Tamsulosin)	vnnkjdsvyc = rhzgesdjbm xjjnzzerse (nnyzjnojya, inonojsslf - pvpsxvpfst) View more
NCT02656173 (MATCH, Pubmed \| Adv Ther)	Phase 4	Urinary Bladder, Overactive Add-on	568	Mirabegron 50 mg + Tamsulosin	nufupoutut(cuotitogvs) = uopsbxlsxr fpwflxouyc (inystpsyzo ) View more	-	01 Jan 2021
				Placebo + Tamsulosin	nufupoutut(cuotitogvs) = tjmudzyugb fpwflxouyc (inystpsyzo ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Tamsulosin Hydrochloride

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation